Jiangsu Sihuan Bioengineering Co Ltd

Jiangsu Sihuan Bioengineering Co Ltd has a market capitalization of 3.33 billion CNY and a price-to-book ratio of 9.94, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 3.63, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -28.92 million CNY, and its operating cash flow is 78.12 million CNY, indicating that it is not generating enough cash from operations to fund its capital expenditures. The company's profitability is weak, with a net loss of 37.09 million CNY and an operating loss of 41.14 million CNY. Its return on equity is -11.08%, and its return on assets is -7.51%, both significantly below the industry median for pharmaceutical companies. The company's gross profit margin is 36.38%, which is in line with the industry median, but its operating margin is -11.92%, indicating poor operational efficiency. Jiangsu Sihuan Bioengineering Co Ltd's revenue is concentrated in a single geographic region, with all of its revenue generated in China. The company does not disclose segment-level revenue, making it difficult to assess the performance of its different product lines or therapeutic areas. The company's revenue for the latest period is 344.38 million CNY, and its revenue growth is not disclosed. The company's debt-to-equity ratio is 0.13, indicating a relatively low level of leverage. However, its net cash position is negative after subtracting total debt, which could pose a liquidity risk if the company's cash flow from operations does not improve. The company's capital expenditures are -3.60 million CNY, indicating that it is not investing in new assets. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company's shares outstanding are 1.03 billion, and there is no indication of near-term dilution pressure. The company's recent financial performance, including a net loss and negative operating income, suggests that it may need to raise additional capital in the future. The company's recent financial filings indicate a challenging operating environment, with a net loss and negative operating income. The company's recent earnings per share (EPS) was -0.14 CNY, and its revenue for the latest period was 179.21 million CNY, which is significantly lower than its total revenue of 344.38 million CNY. The company's recent performance suggests that it is facing headwinds in its core markets.